Triptorelin-Linked Trial lidERA Update: Phase 3 Status Active, Not Recruiting

On October 15, 2026, a status update was recorded for the Phase 3 clinical trial known as lidERA Breast Cancer, registered as NCT04961996. The trial is titled "A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer." Triptorelin is listed among the compounds associated with this study. According to the update, the trial's current status is active but not recruiting new participants. The trial is designated as Phase 3, indicating it is in a later stage of clinical evaluation. No results or outcome data were included in this update. The listing does not state efficacy, safety findings, or comparative performance between the study arms. This brief reflects only the status change recorded on the specified date and does not represent new findings or conclusions. Readers interested in triptorelin's approved uses and general background can consult the compound overview for further context.